Paragraph 4 Insertion of regulation 27A (fee for renewals of a marketing authorisation)I1
United Kingdom
After regulation 27, insert—
“Fee for renewals of a marketing authorisation
27AWhere an application is made to the licensing authority for the renewal of a marketing authorisation F1in the case of a product for sale or supply in Great Britain and the application for renewal—
(a)relates to a medicinal product which, at the time the marketing authorisation was granted, contained a new active ingredient; and
(b)is the first renewal in relation to that product,
the fee payable by the applicant is the fee prescribed in Part 6 of Schedule 2.”.
Annotations
Textual amendments
- F1
Words in Sch. 1 para. 4 inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 188(e)
Commencement
- I1
Sch. 1 para. 4 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1